Pharsight

Drugs that contain Berotralstat Hydrochloride

1. Orladeyo patents expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(10 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11708333 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

US11618733 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-333) Dec 03, 2027
New Chemical Entity Exclusivity(NCE) Dec 03, 2025

NCE-1 date: 03 December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

Family Patents